Header Logo

Connection

Kerstin Stenson to Male

Back to Details
This is a "connection" page, showing publications Kerstin Stenson has written about Male.
Kerstin Stenson
Connection Strength
0.717
Male
  1. Enhanced recovery after surgery in head and neck surgery: Reduced opioid use and length of stay. Laryngoscope. 2020 05; 130(5):1227-1232.
    View in: PubMed
    Score: 0.052
  2. Airway management before chemoradiation for advanced head and neck cancer. Head Neck. 2012 Feb; 34(2):254-9.
    View in: PubMed
    Score: 0.029
  3. Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope. 2010 Jan; 120(1):93-9.
    View in: PubMed
    Score: 0.027
  4. Neck dissection planning based on postchemoradiation computed tomography in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009 Sep; 135(9):876-80.
    View in: PubMed
    Score: 0.026
  5. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21.
    View in: PubMed
    Score: 0.026
  6. Aspiration in chemoradiated patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2007 Dec; 133(12):1289-95.
    View in: PubMed
    Score: 0.023
  7. Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006 Jan; 116(1):33-6.
    View in: PubMed
    Score: 0.020
  8. Laryngeal Chondrosarcoma Characteristics and Survival Analysis in the National Cancer Database. Otolaryngol Head Neck Surg. 2022 01; 166(1):101-108.
    View in: PubMed
    Score: 0.015
  9. Cytopathologic assessment of gloves and instruments after major head and neck surgery. Am J Otolaryngol. 2021 May-Jun; 42(3):102876.
    View in: PubMed
    Score: 0.014
  10. Functional outcomes after extracapsular dissection with partial facial nerve dissection for small and large parotid neoplasms. Am J Otolaryngol. 2021 Jan - Feb; 42(1):102770.
    View in: PubMed
    Score: 0.014
  11. Willingness of patients to attend abdominal aortic aneurysm surveillance: The implications of COVID-19 on restarting the National Abdominal Aortic Aneurysm Screening Programme. Br J Surg. 2020 12; 107(13):e646-e647.
    View in: PubMed
    Score: 0.014
  12. Occult Lymph Node Metastasis in Early-Stage Glottic Cancer in the National Cancer Database. Laryngoscope. 2021 04; 131(4):E1139-E1146.
    View in: PubMed
    Score: 0.014
  13. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg. 2000 Aug; 126(8):950-6.
    View in: PubMed
    Score: 0.014
  14. Enhanced recovery protocol for transoral robotic surgery demonstrates improved analgesia and narcotic use reduction. Am J Otolaryngol. 2020 Nov - Dec; 41(6):102649.
    View in: PubMed
    Score: 0.014
  15. Swallowing function in patients with head and neck cancer prior to treatment. Arch Otolaryngol Head Neck Surg. 2000 Mar; 126(3):371-7.
    View in: PubMed
    Score: 0.014
  16. Prognostic Indicators in Base of Tongue Adenocarcinoma: A Population-Based Analysis. Ear Nose Throat J. 2021 Sep; 100(5_suppl):467S-471S.
    View in: PubMed
    Score: 0.013
  17. Association of Perioperative Opioid-Sparing Multimodal Analgesia With Narcotic Use and Pain Control After Head and Neck Free Flap Reconstruction. JAMA Facial Plast Surg. 2019 Sep 01; 21(5):446-451.
    View in: PubMed
    Score: 0.013
  18. Heterogeneity in the clinical presentation, diagnosis, and treatment initiation of p16-positive oropharyngeal cancer. Am J Otolaryngol. 2019 Sep - Oct; 40(5):626-630.
    View in: PubMed
    Score: 0.013
  19. Clinical features and outcomes in young adults with oral tongue cancer. Am J Otolaryngol. 2019 Jan - Feb; 40(1):93-96.
    View in: PubMed
    Score: 0.012
  20. Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. Oral Oncol. 2018 05; 80:16-22.
    View in: PubMed
    Score: 0.012
  21. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9.
    View in: PubMed
    Score: 0.010
  22. Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13.
    View in: PubMed
    Score: 0.010
  23. Hemangiopericytoma of the oral cavity. Otolaryngol Head Neck Surg. 1996 Feb; 114(2):339-40.
    View in: PubMed
    Score: 0.010
  24. Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205.
    View in: PubMed
    Score: 0.009
  25. Pathologic quiz case 2. Burn scar carcinoma (BSC). Arch Otolaryngol Head Neck Surg. 1994 Sep; 120(9):1016-7, 1020-1.
    View in: PubMed
    Score: 0.009
  26. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb 01; 21(3):632-41.
    View in: PubMed
    Score: 0.009
  27. Lymph node density--prognostic value in head and neck cancer. Head Neck. 2014 Feb; 36(2):266-72.
    View in: PubMed
    Score: 0.009
  28. Experience with one-stage laryngotracheal reconstruction. Int J Pediatr Otorhinolaryngol. 1993 May; 27(1):55-64.
    View in: PubMed
    Score: 0.008
  29. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade? Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
    View in: PubMed
    Score: 0.008
  30. Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. Oral Oncol. 2013 Mar; 49(3):277-82.
    View in: PubMed
    Score: 0.008
  31. Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncol. 2012 Oct; 48(10):1025-1030.
    View in: PubMed
    Score: 0.008
  32. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15; 18(8):2336-43.
    View in: PubMed
    Score: 0.008
  33. Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer. Am J Clin Oncol. 2011 Aug; 34(4):356-61.
    View in: PubMed
    Score: 0.008
  34. Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol. 2011 Jul 26; 3:31.
    View in: PubMed
    Score: 0.008
  35. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011 Oct 15; 117(20):4671-8.
    View in: PubMed
    Score: 0.007
  36. Cystic hygroma of the parotid gland. Ann Otol Rhinol Laryngol. 1991 Jun; 100(6):518-20.
    View in: PubMed
    Score: 0.007
  37. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Nov; 22(11):2501-2507.
    View in: PubMed
    Score: 0.007
  38. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol. 2011 Oct; 22(10):2304-9.
    View in: PubMed
    Score: 0.007
  39. Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. Head Neck. 2010 Nov; 32(11):1519-27.
    View in: PubMed
    Score: 0.007
  40. Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. Radiother Oncol. 2010 Nov; 97(2):318-21.
    View in: PubMed
    Score: 0.007
  41. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43.
    View in: PubMed
    Score: 0.007
  42. Chemoreirradiation for recurrent salivary gland malignancies. Radiother Oncol. 2010 Jun; 95(3):308-11.
    View in: PubMed
    Score: 0.007
  43. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57.
    View in: PubMed
    Score: 0.006
  44. Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008 Oct; 134(10):1060-5.
    View in: PubMed
    Score: 0.006
  45. Free-flap reconstruction in the doubly irradiated patient population. Plast Reconstr Surg. 2008 Jul; 122(1):125-132.
    View in: PubMed
    Score: 0.006
  46. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol. 2008 Oct; 19(10):1787-94.
    View in: PubMed
    Score: 0.006
  47. Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann Oncol. 2008 Sep; 19(9):1650-4.
    View in: PubMed
    Score: 0.006
  48. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
    View in: PubMed
    Score: 0.006
  49. The thoracoacromial trunk: alternative recipient vessels in reoperative head and neck reconstructive microsurgery. Plast Reconstr Surg. 2008 Jan; 121(1):88-94.
    View in: PubMed
    Score: 0.006
  50. A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer. Cancer Invest. 2007 Sep; 25(6):435-44.
    View in: PubMed
    Score: 0.006
  51. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20; 24(21):3438-44.
    View in: PubMed
    Score: 0.005
  52. A simplified design of a dual island fasciocutaneous free flap for simultaneous pharyngoesophageal and anterior neck reconstruction. J Reconstr Microsurg. 2006 Feb; 22(2):105-12.
    View in: PubMed
    Score: 0.005
  53. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1096-106.
    View in: PubMed
    Score: 0.005
  54. Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. Cancer J. 2005 Mar-Apr; 11(2):140-6.
    View in: PubMed
    Score: 0.005
  55. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004 Aug; 15(8):1179-86.
    View in: PubMed
    Score: 0.005
  56. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Cancer Res. 2004 Aug 01; 10(15):4922-32.
    View in: PubMed
    Score: 0.005
  57. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004 May; 26(5):447-55.
    View in: PubMed
    Score: 0.005
  58. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 2004 Mar 15; 10(6):1956-62.
    View in: PubMed
    Score: 0.005
  59. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43.
    View in: PubMed
    Score: 0.004
  60. Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst. 2003 Sep 17; 95(18):1370-5.
    View in: PubMed
    Score: 0.004
  61. Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary. Ann Oncol. 2003 Aug; 14(8):1306-11.
    View in: PubMed
    Score: 0.004
  62. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003 May 15; 21(10):1980-7.
    View in: PubMed
    Score: 0.004
  63. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
    View in: PubMed
    Score: 0.004
  64. Radiology quiz case 2. Verrucous carcinoma of the maxillary antrum. Arch Otolaryngol Head Neck Surg. 2003 Feb; 129(2):259, 260-1.
    View in: PubMed
    Score: 0.004
  65. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6.
    View in: PubMed
    Score: 0.004
  66. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol. 2001 Apr 01; 19(7):1961-9.
    View in: PubMed
    Score: 0.004
  67. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer. Cancer J. 2001 Mar-Apr; 7(2):140-8.
    View in: PubMed
    Score: 0.004
  68. A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer. Ann Oncol. 2000 Jun; 11(6):721-8.
    View in: PubMed
    Score: 0.003
  69. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000 Apr; 18(8):1652-61.
    View in: PubMed
    Score: 0.003
  70. Patients' priorities among treatment effects in head and neck cancer: evaluation of a new assessment tool. Head Neck. 1999 Sep; 21(6):538-46.
    View in: PubMed
    Score: 0.003
  71. Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. J Clin Oncol. 1999 Mar; 17(3):1020-8.
    View in: PubMed
    Score: 0.003
  72. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res. 1999 Feb; 5(2):291-8.
    View in: PubMed
    Score: 0.003
  73. Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. J Clin Oncol. 1999 Feb; 17(2):638-44.
    View in: PubMed
    Score: 0.003
  74. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 1998 Feb; 16(2):735-44.
    View in: PubMed
    Score: 0.003
  75. Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. Semin Oncol. 1997 Feb; 24(1 Suppl 2):S2-68-S2-71.
    View in: PubMed
    Score: 0.003
  76. The role of paclitaxel in the treatment of head and neck cancer. Semin Oncol. 1995 Oct; 22(5 Suppl 12):8-12.
    View in: PubMed
    Score: 0.003
  77. Effects of plume produced by the Nd:YAG laser and electrocautery on the respiratory system. Lasers Surg Med. 1993; 13(2):242-5.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.